We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » J&J is Latest Big Drugmaker to Limit Participation in the 340B Drug Discount Program
J&J is Latest Big Drugmaker to Limit Participation in the 340B Drug Discount Program
Johnson & Johnson (J&J) is further curtailing its participation in the controversial 30-year-old 340B Drug Discount Program, which was designed to serve low-income patient populations in the U.S.